Last reviewed · How we verify

NCT05509829: LAUREN

EvaLuating negAtive pressUre Wound theRapy in brEast coNserving Surgery

Status unknown NA Last updated 7 July 2023
What this trial tests

NA trial testing Negative pressure wound therapy in Breast Cancer in 300 participants. Status unknown.

Timeline
1 May 2023
Primary endpoint
1 September 2023
1 December 2023

Quick facts

Lead sponsorZuyderland Medisch Centrum
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationnon randomized
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment300
Start date1 May 2023
Primary completion1 September 2023
Estimated completion1 December 2023
Sites1 location across Netherlands

Drugs / interventions tested

Conditions studied

Sponsor

Zuyderland Medisch Centrum — full company profile →

Who can join

18 and older, female only, with Breast Cancer or Seroma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Negative pressure wound therapy (NPWT) could improve surgical outcomes and reduce complications like SSI, wound dehiscence and seroma in closed surgical wounds. To date, NPWT was not evaluated in patients undergoing breast conserving surgery without direct reconstruction.Therefore, the aim of this trial is to evaluate the feasibility of NPWT after surgery and its effects on postoperative complications.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Negative pressure wound therapy

Trials testing the same drug.

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

Other Zuyderland Medisch Centrum trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05509829.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing